| Literature DB >> 31352701 |
Ather Muneer1, Fareed Aslam Minhas2.
Abstract
Major psychiatric disorders are linked to early mortality and patients afflicted with these ailments demonstrate an increased risk of developing physical diseases that are characteristically seen in the elderly. Psychiatric conditions like major depressive disorder, bipolar disorder and schizophrenia may be associated with accelerated cellular aging, indicated by shortened leukocyte telomere length (LTL), which could underlie this connection. Telomere shortening occurs with repeated cell division and is reflective of a cell's mitotic history. It is also influenced by cumulative exposure to inflammation and oxidative stress as well as the availability of telomerase, the telomere-lengthening enzyme. Precariously short telomeres can cause cells to undergo senescence, apoptosis or genomic instability; shorter LTL correlates with compromised general health and foretells mortality. Important data specify that LTL may be reduced in principal psychiatric illnesses, possibly in proportion to exposure to the ailment. Telomerase, as measured in peripheral blood monocytes, has been less well characterized in psychiatric illnesses, but a role in mood disorder has been suggested by preclinical and clinical studies. In this manuscript, the most recent studies on LTL and telomerase activity in mood disorders are comprehensively reviewed, potential mediators are discussed, and future directions are suggested. An enhanced comprehension of cellular aging in psychiatric illnesses could lead to their re-conceptualizing as systemic ailments with manifestations both inside and outside the brain. At the same time this paradigm shift could identify new treatment targets, helpful in bringing about lasting cures to innumerable sufferers across the globe.Entities:
Keywords: Aging; Leukocyte telomere length; Mood disorders; Mortality.; Telomerase activity
Year: 2019 PMID: 31352701 PMCID: PMC6705109 DOI: 10.9758/cpn.2019.17.3.343
Source DB: PubMed Journal: Clin Psychopharmacol Neurosci ISSN: 1738-1088 Impact factor: 2.582
Leukocyte telomere length (LTL) studies in mood disorders: summary of main findings
| Study | Population studied | Subjects (n) | Mean age (yr) | Mean duration of ill-ness (yr) | Mean TL | LTL assay technique | Chief findings | Additional notes |
|---|---|---|---|---|---|---|---|---|
| Major depressive disorder (MDD) | ||||||||
| Simon | Chronic MDD & BD cases with or without comorbid ADs | 44/44 | 51/51 | 32 | 6.98/7.64 kb | Southern blot | Significantly shorter LTL in mood disorders | Active physical illnesses excluded in subjects. No data on the possible association between duration of illness and telomere shortening. |
| Hartmann | Inpatients with MDD | 54/20 | 49/49 | 15 | 7.20/7.55 kb | Southern blot | Statistically significant shorter LTL in MDD | Psychiatric and physical comorbidity not excluded in MDD subjects. Association between chronicity/severity of MDD and telomere shortening was not shown. Potential confounding factors were not controlled for. |
| Hoen | Outpatients with CHD with or without MDD | 206/746 | 62/68 | Not documented | 0.86/0.90 (T/S ratio) | Q-PCR | LTL significantly shorter in subjects with MDD | The association between LTL and MDD may have been confounded by greater cardiac disease severity in the depression group. When full covariates were analyzed, LTL difference just missed significance ( |
| Wolkowitz | Un-medicated MDD outpatients and matched controls | 18/17 | 37/37 | 13 | 5,101/5,141 (bp) | Q-PCR | LTL not significantly different in cases versus controls. However, shorter LTL was noted in long-standing MDD cases. | Shorter LTL observed in those MDD cases who had more lifetime days of untreated depression. LTL inversely correlated with peripheral circulating levels of proinflammatory cytokines and oxidative stress markers. Study limited by small sample size. |
| Teyssier | MDD subjects and matched controls | 17/16 | 40/38 | 12 of the MDD subjects were 1st episode | 13.42/13.60 | Q-PCR | LTL not significantly different in the two groups. Physical comorbidity was excluded, particularly, CVD. Psychiatric comorbidity also excluded. Anxiety symptoms may have been present. | MDD subjects had increased expression of certain genes involved in telomere maintenance. Also, in MDD subjects increased expression of an enzyme involved in repair of oxidative damage to the DNA. |
| Hoen | Two population based samples of subjects with ASD and DD and controls | ASD: 108/970 | ASD: 52/54 | NA | NA | Q-PCR | The presence of ASD and not DD over the preceding year predicted significant LTL shortening 2.2 years later. | Strength of the study is its prospective design. |
| Verhoeven | Current and remitted MDD patients from the NESDA cohort | Current MDD subjects: 1,095 | 41/41 | MDD duration in the current group: 21 mo | 5,474/5,553 bp | Q-PCR | Statistically significant shorter LTL in current and remitted MDD compared to controls. | Within the current MDD subjects, both higher depression severity and longer symptom duration were associated with shorter LTL. Telomere shortening in the remitted group was not correlated to the number of years in remission and use of antidepressant medications. LTL shortening in both MDD groups remained significant even after adjusting for somatic comorbidity. |
| Shalev | Sample consisted of subjects with internalizing disorders including MDD. It was derived from the birth cohort of the Dunedin Multidisciplinary Development Study. | Internalizing disorder from age 11 to 38 yr: 455 | Longitudinal study from 11–38 yr old | NA | NA | Q-PCR | The persistence of “internalizing disorder” diagnoses between ages 11–38 yr predicted shorter LTL at age 38 yr in a dose-response manner in men, but not in women. | High co-morbidity between different internalizing disorders such as GAD, PTSD. Approximately 75% of the study subjects had exceeded clinical cut-off for one or more of such physical health parameters as metabolic abnormalities, cardiorespiratory fitness, and systemic inflammation. |
| Needham | MDD | 75/96 | 30.3/29.2 | NA | 1.12/1.14 (T/S ratio) | Q-PCR | LTL not significantly different in the two groups. However, in MDD subjects taking antidepressant medications LTL was significantly shorter than control. This may be because of greater severity of depression in the MDD subgroup. | Relatively young cohort |
| Schaakxs | Late life depression | 355/128 | 70.6/70.1 | NA | 5,036/5,055 bp | Q-PCR | No significant difference in LTL. | Age and the number of chronic medical diseases were significantly inversely correlated with LTL. However, presence of major depression, severity and number of depressive episodes were not. Controlling for medication use, chronic medical illnesses and lifestyle factors did not change the results. |
| Bipolar disorder (BD) | ||||||||
| Simon | BD subjects with/without ADs | Total patients 44/controls 44. Fifteen patients with MDD, 15 with BD and co-occurring AD and 14 with BD and no AD | 51.5/50.5 | 35 | 7,030/7,640 bp | Southern blot | Across all mood disorder subjects LTL was significantly shorter than control. | Patients had chronic MDD or BD. Somatic comorbidity was excluded but psychiatric conditions, particularly AD were not. |
| Elvsåshagen | Outpatients with BD type II–16 patients were euthymic and 12 had depressive episode, mild or moderate. | 28/28 | 35/35 | 19 | 10,067/10,619 bp | Quantitative FISH technique | LTL shortening not statistically significant in BD versus control. However, load of short telomeres was significantly greater in BD. | The load of short telomeres and TL were not significantly correlated with illness duration. |
| Rizzo | BD type I, all female samples. BD subjects had higher titers of IgG antibody against CMV. | 22/17 | 39.5/44.6 | 9.45 | 0.71/0.90 (T/S ratio) | Q-PCR | BD subjects had significantly shorter LTL as compared to controls. | Major psychiatric and physical comorbid conditions controlled for. Results were biased as CMV IgG levels were associated with expansion of senescent CD8 + CD28 T cells and with shorter LTL in BD subjects. |
| Martinsson | BD patients along with age and sex matched controls. BD subjects were on lithium treatment. | 202/135 | NA | NA | NA | Q-PCR | LTL significantly longer in BD subjects compared to controls. | TL positively correlated with lithium treatment duration of >30 mo ( |
| Lima | Patients with BD type I and II, matched controls. Patients had relatively high psychiatric comorbidity, especially AD. | 85/95 | 38/39 | NA | NA | PCR | Patients had significantly shorter TL than controls ( | No information regarding illness duration was given. Smoking, BMI, medication use and somatic illnesses were not controlled for. |
| Barbé-Tuana | BD type I outpatients meeting remission criteria according to defined scores on HRSD and YMRS. | 26/34 | 46.5/44 | 15.25 | 0.75/1.50 (T/S ratio, calculated from graph) | Real time Q-PCR | TLwas significantly shorter in both the early and late subgroups of BD subjects when compared to the respective controls ( | Early stage patients had average disease duration of 8 yr. Late stage cases had mean disease duration of 22.50 yr. All BD subjects were on pharmacotherapy. Small sample size precluded the analysis of the effect of pharmacotherapy on TL. |
TL, telomere length; AD, anxiety disorder; kb, kilobase; CHD, chronic heart disease; T/S, telomere repeat (T) copy number to single (S) copy number; Q-PCR, quantitative polymerase chain reaction; bp, base pair; CVD, cardiovascular disease; ASD, anxiety spectrum disorders; DD, depressive disorders (MDD & dysthymia); NA, not available; NESDA, Netherlands Study of Depression and Anxiety; GAD, generalized anxiety disorder; PTSD, post-traumatic stress disorder; BMI, body mass index; FISH, florescence in situ hybridization; IgG, immunoglobulin G; CMV, cytomegalovirus; HRSD, Hamilton Rating Scale for Depression; YMRS, Young Mania Rating Scale.
Psychiatric/controls.
Mean Ct ratio: cycle threshold for telomeric signal relative to cycle threshold for single copy gene.
Fig. 1Epidemiological studies have consistently shown an association between increased rate of telomere shortening and accelerated aging. Shortened telomeres portend increased morbidity and mortality through cardiovascular diseases, cancers, and other major physical ailments. Patients suffering from chronic psychiatric disorders, for example schizophrenia and mood disorders have significantly decreased life spans compared to controls. Recent studies reveal that this connection may be mediated by accelerated attrition rate of telomeres. See text for full details. HPA, hypothalamic-pituitary-adrenal; CV, cardiovascular.